Anti-HIV drugs

Progress in Brain Delivery of Anti-HIV Drugs

Article history: Received on: 17/01/2015 Revised on: 22/04/2015 Accepted on: 17/06/2015 Available online: 27/07/2015 The HIV/AIDS pandemic is an increasing global burden with devastating health-related and socioeconomic effects. The widespread use of antiretroviral therapy has dramatically improved life quality and expectancy of infected individuals. But currently available drug regimens and do...

Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs.

It is imperative to continue efforts to identify novel effective therapies that can assist in containing the spread of HIV. Recently acquired knowledge about the HIV entry process points to new strategies to block viral entry. For most HIV strains, the successful infection of their target cells is mainly dependent on the presence of the CD4 surface molecule, which serves as the primary virus re...

Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.

OBJECTIVES The safety and effectiveness of highly active antiretroviral therapy (HAART) is challenged by viral resistance to antiretrovirals and the frequent occurrence of drug interactions which may limit the access of these drugs to the target sites. In particular, drug distribution and elimination may be modified by active efflux transporters. While P-glycoprotein is well evaluated in this r...

Crystal Forms of Anti-HIV Drugs: Role of Recrystallization

Does brain penetration of anti-HIV drugs matter?

Soon after the introduction of protease inhibitors and the widespread use of combination antiretroviral therapy, the concept of eradication of HIV-1 from infected individuals seemed a realistic goal. 1 However, the possibility that sanctuaries for virus existed within anatomical sites, such as the central nervous system (CNS), that are protected from the peripheral immune response and that may ...